Emergent BioSolutions (STU:ER4) PEG Ratio: N/A (As of Jul. 09, 2026)


STU:ER4 Emergent BioSolutions Inc STU:ER4
55 GF Score
Price €7.17
GF Value €4.17
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Emergent BioSolutions's PE Ratio without NRI is 8.36. Emergent BioSolutions's 5-Year EBITDA growth rate is 0.00%. Therefore, Emergent BioSolutions's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Emergent BioSolutions's PEG Ratio or its related term are showing as below:


During the past 13 years, Emergent BioSolutions's highest PEG Ratio was 12.47. The lowest was 0.16. And the median was 0.86.


STU:ER4's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.725
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Emergent BioSolutions  (STU:ER4) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Emergent BioSolutions PEG Ratio Related Terms


Emergent BioSolutions PEG Ratio Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions PEG Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.00 0.00 0.00 0.00

Emergent BioSolutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:ER4 vs ELTP, NIKA, EOLS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's PEG Ratio falls into.


STU:ER4
55GF Score
Emergent BioSolutions Inc STU:ER4
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Emergent BioSolutions's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=8.3605600933489/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €7.17 is trading 71.8% above its estimated GF Value™ of €4.17. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • PEG Ratio: N/A
  • GF Value™: €4.17 vs. price of €7.17 (71.8% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
55GF Score

Get the complete analysis for STU:ER4

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.17
Price
€4.17
GF Value